Oral anticoagulation in patients with acute heart failure | Synapse
May 17, 2026
Oral anticoagulation in patients with acute heart failure
Key Points
The research evaluates the impact of oral anticoagulation on mortality and thromboembolic events in patients with acute heart failure.
Randomized trial design
Inclusion of patients with acute heart failure
Comparison between anticoagulation therapy and standard care
Patients receiving oral anticoagulation experienced a reduction in thromboembolic events by 30% (OR 0.70, 95% CI 0.50-0.95, P=0.02).
Reduction in all-cause mortality observed, with a rates of 15% in the anticoagulation group vs. 22% in standard care (HR 0.67, 95% CI 0.50-0.90, P=0.01).